API Holdings (Pharmeasy): Financial Results for FY24
Written by: Diksha Kalra
Published: Sep 16, 2026
Updated: Sep 16, 2026
1 min read
- Revenue- In FY24, the company’s revenue dropped by 15%, decreasing from Rs. 6,644 cr in FY23 to Rs. 5,664 cr. This decline was primarily due to reduced sales in both trading and distribution of pharmaceutical and cosmetic goods, as well as services. However, despite the revenue fall, the company managed to reduce its net loss, which improved from Rs. -5,212 cr in FY23 to Rs. -2,534 cr in FY24. This improvement also reflected in the EPS, which increased from Rs. -9 in FY23 to Rs. -4 in FY24.
- Financial performance- The company’s overall asset base saw a modest increase of 2%, rising from Rs. 8,256 cr in FY23 to Rs. 8,390 cr in FY24. Additionally, the company’s total equity grew by 6%, moving from Rs. 2,437 cr in FY23 to Rs. 2,588 cr in FY24.
Stay Connected, Stay Informed –
Join Our
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Planify Enterprises Private Limited
Planify Capital Limited
Licensed By
Mutual Fund License No.:
ARN-164419
IRDA Code (1):
ABLIC1003123454
IRDA Code (2):
ABLIC1003131639
Startup India Certificate No.:
DIPP93786
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India
